AANEM News Express

AANEM News Express

Science News: Neurofascin IgG4 Antibodies in CIDP Associate With Disabling Tremor and Poor Response

4/18/2014
 
Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurology 2014;82:879-886.
Submitted by Andrew Tarulli, MD

science news image of blue neuronAbout the Study

Immunocytochemical methods were used to identify antibodies to the paranodal protein neurofascin 155 (NF155) in 4 of 61 patients with chronic inflammatory demyelinating polyneuropathy (CIDP). All of the patients had disabling (modified Rankin Scale scores of 4), predominantly distal weakness that was refractory to treatment with intravenous immunoglobulin (IVIg). Two of the patients were identified from a local sample of 53 patients with CIDP. The other 2 patients were from a national pool of 8 patients with previously-identified CIDP refractory to IVIg. Disabling tremor and ataxia was present in 3 of the 4 patients.

Comment

CIDP is readily diagnosed by finding a combination of proximal and distal weakness, nerve conduction studies showing acquired demyelination, and albuminocytological dissociation. There are, however, no biomarkers that predict response to therapy reliably: while most patients improve with intravenous immunoglobulin, a small subset remain refractory and need other immunosuppressive treatments. Identification of antibodies to components of peripheral nerve associated with specific phenotypes would be an important aid in optimizing treatment.

Querol and colleagues identified antibodies associated with NF155, a paranodal protein necessary for the formation of septate-like axo-glial junctions. Knockout of NF155 in mice produces a severe demyelinating polyneuropathy with prominent tremor and ataxia, similar to that seen in the patients in this study. The investigators noted that the NF155 antibodies were of the IgG4 isotype, which do not activate complement or bind to Ig Fc domain receptors, both of which are likely mechanisms of IVIg and thus, potential explanations for the lack of responsiveness to IVIg in this subset. Verification of the results of this study in other patients with CIDP, especially IVIg-refractory CIDP with tremor and ataxia is necessary.



View Related News Stories:

  EducationScience News


Recent AANEM News

Recap: 2019 AMA House of Delegates Annual Meeting

Science News: Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy

Science News: Diagnostic Sensitivity of Electrophysiology and Ultrasonography in Ulnar Neuropathies of Different Severity

Science News: Long-term Effect of Thymectomy Plus Prednisone Versus Prednisone Alone in Patients with Non-thymomatous Myasthenia Gravis: 2-year Extension of the MGTX Randomised Trial

AANEM Returns to Capitol for 6th Annual Hill Day





Advertisement

TPP

Advertisement

ABEM

Advertisement

Find Your Dream Job